Origo Biopharma is a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders
Origo Biopharma is a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. The company has developed novel organ-restricted small molecule entities to maximize the potential of local TGF-β inhibition while avoiding systemic toxicities.